NVB 302

Drug Profile

NVB 302

Alternative Names: NVB302

Latest Information Update: 22 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novacta Biosystems
  • Developer Novacta
  • Class Antibacterials; Bacteriocins; Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Clostridium infections

Most Recent Events

  • 22 Jan 2016 NVB 302 is still in phase I development for Clostridium infections in United Kingdom
  • 24 Aug 2011 Phase-I clinical trials in Clostridium infections in United Kingdom (PO)
  • 15 Sep 2009 Antimicrobial data from a preclinical trial in Bacterial infections presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top